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ABSTRACT
Previous study has suggested that the FABP5-PPARγ-signalling transduction 
pathway gradually replaces the androgen receptor activated pathway in promoting 
malignant progression of castration-resistant prostate cancer (CRPC) cells. To 
interfere with this newly discovered FABP5-related signalling pathway, we have 
produced a highly efficient recombinant FABP5 inhibitor, named dmrFABP5. Treatment 
with dmrFABP5 significantly supressed the proliferation, migration, invasion and 
colony formation of the highly malignant prostate cancer cells PC3-M in vitro. To 
test dmrFABP5’s suppressive effect in CRPC, the human PC3-M cells were implanted 
orthotopically into the prostate gland of immunosuppressed mice to produce tumours. 
These mice were then treated with dmrFABP5 and produced a highly significant 
reduction of 100% in metastatic rate and a highly significant reduction of 13-fold in 
the average size of primary tumours. Immunocytochemial staining showed that the 
staining intensity of dmrFABP5 treated tumours was reduced by 67%. When tested 
in vitro, dmrFABP5 suppressed the cancer cells by blocking fatty acid stimulation 
of PPARγ, and thereby prevented it activating down-stream cancer-promoting or 
inhibiting cancer-suppressing genes. Our results show that the FABP5 inhibitor 
dmrFABP5 is a novel molecule for treatment of experimental CRPC and its inhibitory 
effect is much greater than that produced by SB-FI-26 reported in our previous work.
INTRODUCTION
Prostate cancer is common in countries with a 
high dietary consumption of fatty acids [1]. In the early 
stage, growth and dissemination of prostate cancer cells 
depend on androgen supplied through the peripheral blood 
and thus therapy has been directed towards deprivation 
of androgen. Androgen-deprivation therapy (ADT) 
is initially very effective. However, in most cases the 
disease relapses within 2–3 years with recurrence of lethal 
castration-resistant prostate cancer (CRPC). This disease 
cannot be treated effectively by ADT [2]. The CRPC 
cells overexpress fatty acid synthase (FASN) and acetyl-
CoA carboxylase, which are key enzymes involved in 
the synthesis of fatty acids [3-5]. Fatty acids are not only 
active components of many biological processes, but also 
are essential signal transduction molecules in pathways 
involved in advanced prostate cancer progression [6-8]. 
Thus blocking the supply of fatty acids has become a 
therapeutic strategy to suppress malignant dissemination 
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of prostate and some other cancer cells [9]. 
Fatty acid-binding protein 5, or FABP5, is a 15kDa 
cytosolic protein, which binds with a high affinity to 
medium and long chain fatty acids [10]. After FABP5 had 
been shown to promote malignant progression in prostate 
cancer cells [11-14], its increased expression in archival 
prostate cancer tissues was found to be significantly 
associated with reduced patient survival times. Thus 
FABP5 is now a valuable prognostic factor for advanced 
prostate cancer [15]. Moreover, recent investigations 
have established that there is a novel fatty acid-initiated 
signalling pathway that leads to malignant progression of 
prostatic cancer cells. Thus, when FABP5 expression is 
increased, excessive amounts of fatty acids are transported 
into the nucleus of the prostate cancer cells, where they 
act as signalling molecules to stimulate their nuclear 
receptor PPARγ. The activated PPARγ then modulates 
the expression of its down-stream regulatory genes and 
these changes finally lead to enhanced tumour expansion 
and aggressiveness caused by an overgrowth of cells with 
increased angiogenesis and reduced apoptosis [16]. 
If the malignant progression of CRPC cells can 
be suppressed by inhibiting the biological activity of 
FABP5, the availability of highly effective inhibitors to 
FABP5 is an important first step in testing this hypothesis. 
Inhibition of FABP5’s activity has been shown by using 
chemically synthesized inhibitors, e.g. BMS309403, to 
be effective for treatment of inflammatory and metabolic 
diseases [17-20]. Recently-developed FABP5 inhibitors, 
which produce approximately 50% of the inhibitory effect 
of BMS309403, were originally effective analgesics and 
anti-inflammatory agents in mice [21-23]. These small 
molecule inhibitors included SB-FI-26 (α-truxillic acid 
1-naphthyl mono-ester). This compound was tested in our 
previous work and exhibited a significant suppression of 
both primary tumour growth and metastasis of the CRPC 
cells [24]. SB-FI-26 is, in fact, the active component of 
a traditional herbal medicine (Incarvillea sinensis) which 
has been used to treat pain and rheumatism for hundreds 
of years [25, 26]. 
FABP5 binds to fatty acids through a binding motif 
that consists of 3 key amino acids [27]. Our previous 
work showed that the structural integrity of this fatty 
acid-binding motif is essential for the tumour-promoting 
function of FABP5 [16]. The mutant protein dmrFABP5 
is a recombinant molecule generated by changing 2 of the 
3 amino acids in the fatty acid-binding motif of FABP5. 
Thus dmrFABP5 has lost most of its ability of binding to 
and transporting fatty acids. In this work, we have tested 
the potential of dmrFABP5 as a bio-inhibitor of FABP5 for 
the treatment of CRPC in mice. Moreover, its suppressive 
effects have been compared to those of SB-FI-26 under the 
same conditions.
RESULTS
Production of recombinant FABP5s and testing 
their biological activities
All 3 constructs containing cDNAs for wtrFABP5, 
dmrFABP5 and smrFABP5, respectively, were 
transformed into competent BL21 E. coli cells for 
production of protein. After induction, the wtrFABP5 
recognized by the anti-His tag antibody in the recombinant 
bacteria was gradually expressed and reached its 
maximum after 4 hours (Figure 1A). When extracts were 
Western blotted with a monoclonal anti-human FABP5, 
only a single band in the first fraction was detected for 
each of the 3 recombinant FABP5s indicating that each 
recombinant protein was of high purity. Small amounts 
of the recombinant protein were also present in the 
second elution fraction (Figure 1B). The fatty acid-
binding affinity of wtrFABP5 to the fluorescently labelled 
fatty acid DAUDA was tested and its maximum affinity 
was detected at 530nm, this corresponded to a shift in 
DAUDA’s original emission wavelength (Figure 1C/a). 
The fluorescent intensity decrease when DAUDA was 
displaced from each recombinant FABP5 by palmitic acid 
was used as an indication of their relative binding affinity. 
Addition of palmitic acid to the wtrFABP5-DAUDA 
complex created a noticeable drop in the fluorescent 
intensity (Figure 1C/b). However, addition of palmitic acid 
to smrFABP5- DAUDA complexes was able to produce 
only a small reduction in fluorescent intensity. Addition 
of palmitic acid to dmrFABP5-DAUDA complexes 
produced almost no reduction in fluorescent intensity 
(Figure 1C/c, d). When the level of fluorescent intensity 
of DAUDA (D) + Buffer (B) was set at 1 (Figure 1D), the 
fluorescent intensity of the complex of wtrFABP5, D and 
B without palmitic acid was 2.97 ± 0.08. When palmitic 
acid was added to the complex, the level of fluorescent 
intensity was significantly reduced by 83% to 1.34 ± 0.7 
(Student’s t test, p < 0.0001). Thus wtrFABP5 exhibited a 
strong ability to bind to palmitic acid and displaced 83% 
DAUDA. When palmitic acid was added to complexes of 
smrFABP5 + B +D, the level of fluorescent intensity was 
reduced moderately, but significantly by 30% (Student’s t 
test, p < 0.01). However, when palmitic acid was added to 
complexes of dmrFABP5 + B +D, the level of fluorescent 
intensity was only slightly reduced by 7%, indicating that 
dmrFABP5 was able to replace only 7% of the DAUDA, 
thus dmrFABP5 had lost most of its ability of binding 
to fatty acids. Therefore, when Arg109 was changed to 
Ala109 (smrFABP5) and that change was combined with 
the change of Arg129 to Ala129 (dmrFABP5) (Figure 1E), 
these substitutions either partially or almost completely 
inhibited FABP5’s ability of binding to fatty acids. 
Genes & Cancer3www.Genes&Cancer.com
Figure 1: Production of recombinant FABP5s in E. coli cells and testing their binding affinity to fatty acids. A. Determination by 
Western blot of the optimal time point at which the maximum amount of recombinant protein was synthesized in bacterial cells. 6×His-tag 
bound protein bands were recognized by the Penta-His antibody. The wtrFABP5 protein synthesized at different times is shown in 7 separate 
lanes. Bacterial cells harboring empty plasmid were used as a negative control. B. Western blot analysis of different recombinant FABP5s 
purified by affinity chromatography. Bands of FABP5 protein (collected in eluates E1 and E2) were identified by monoclonal anti-human 
FABP5. C. Representative graphic records of fatty acid binding properties of the recombinant FABP5s by DAUDA displacement assay. a) 
Effect of wtrFABP5 on the fluorescent emission spectra of a fluorescent fatty acid (DAUDA) ligand at the excitation wavelength of 345nm. 
Reaction solutions contained: (1) PBS, (2) wtrFABP5 in PBS, (3) 2µM DAUDA, (4) 2µM DAUDA with 3µM wtrFABP5. b) Competitive 
inhibition of DAUDA binding to wtrFABP5 with palmitic acid. c) Competitive inhibition of DAUDA binding to smrFABP5 with palmitic 
acid. d) Competitive inhibition of DAUDA-dmrFABP5 binding to palmitic acid. For a, b, and c: reaction solutions contained: (1) PBS, 
(2) 3µM X in PBS, (3) 3µM X and 2µM DAUDA, (4) 3µM X and 2µM DAUDA plus 2µM palmitic acid. X = wrtFABP5, smrFABP5 or 
dmrFABP5. D. Fluorescent intensities of displaced DAUDA from different recombinant FABP5s by palmitic acid as an indication of their 
relative fatty acid-binding ability. The value produced by the buffer and DAUDA plus FABP5s was set at 1 as control. The results (mean 
± SE) were obtained from 3 separate experiments (2-tailed unpaired Student’s t test, ***, p < 0.0001; *p <0.05). E. Protein sequence of 
human FABP5 (Source: UniProtKB – Q01469, FABP5_HUMAN): Three key amino acids of the fatty acid-binding motif were highlighted.
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Figure 2: DmrFABP5 significantly suppressed the proliferation, migration, invasion and anchorage-independent 
growth of PC3-M cells. A. Testing the optimal inhibitory concentration of dmrFABP5 by calculating viable cell numbers measured 
by the MTT assay. B. Inhibitory effect of 0.5µM dmrFABP5 on proliferation of PC3-M cells over the 6-day experimental period. C. 
Representative images of the wound healing assay. Cell migration capacity was measured by the reduction in wound size in control (1) and 
in cultures treated with 0.5µM dmrFABP5 (2) measured at 0, 12 and 24 hours after treatment. Scale bar is 250µm. D. Average wound sizes 
(µm) of the control PC3-M cells and of cells treated with 0.5µM dmrFABP5 at 0, 12 and 24 hours after treatment. E. Numbers of invading 
cells from the control (1) and from cells treated with 0.5µM dmrFABP5 (2) for 24h after different treatments. Results (mean ± SE) were 
obtained from three separate measurements. Scale bar is 250 µm. F. Colonies produced in soft agar by the control (1) and by cells treated 
with 0.5µM dmrFABP5 (2) 2 weeks after the different treatments. Results (mean ±SE) were obtained from three separate wells in each 
treatment. All in vitro results were subjected to 2-tailed unpaired Student’s t test and *, p < 0.05; **, p < 0.001; ***, p < 0.0001. 
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Inhibitory effect of dmrFABP5 on malignant 
characteristics of PC3-M cells
The effects of dmrFABP5 on the malignant 
characteristics of the PC3-M cells are shown in Figure 
2. Cytotoxicity tests showed that treatment of PC3-M 
cells with dmrFABP5 significantly suppressed their 
viability in a concentration-dependent manner. Maximum 
suppression was observed at 0.5µM dmrFABP5; further 
increases in concentration did not produce any further 
significant suppression. When treated with this optimal 
concentration, cell numbers were significantly reduced 
by 35% (Student’s t test, P < 0.001) (Figure 2A). When 
the same cells were tested using a MTT assay, 0.5µM 
dmrFABP5 significantly reduced their proliferation rate by 
4.7- fold (Student’s t test, P < 0.0001) (Figure 2B). When 
tested in a cell migration assay (Figure 2C), the same cells 
treated with dmrFABP5 produced only a 21% reduction in 
wound size in 24h. These treatments significantly inhibited 
the migration rates of PC3-M cells (Student’s t test, p < 
0.0001), leading to only small wound closures for treated 
groups compared to an almost complete wound closure 
(94%) for the control (Figure 2D). When tested in an 
invasion assay, the mean number of invaded cells from 
the control PC3-M cells and the same cells treated with 
dmrFABP5 was 2 ± 1, representing a significant inhibition 
of invasion by 91% (Student’s t test, P < 0.0001) (Figure 
2E). Further tests in soft agar showed that the number of 
colonies formed after 2 weeks by control PC3-M cells 
and PC3-M cells treated with dmrFABP5 were 124 ± 18, 
and 23 ± 2, respectively, representing a highly significant 
inhibition by 81% (Student’s t test, p < 0.001) (Figure 2F). 
Effect of dmrFABP5 on tumorigenicity and 
metastatic ability of PC3-M cells in mouse 
prostate gland
PC3-M cells were transfected with the 
luciferase vector and 3 colonies which generated high 
bioluminescent signals were picked and named PC3-M-
Luc8, PC3-M-Luc21, and PC3-M-Luc18 (Figure 3A). 
PC3-M-Luc8 produced the highest level of bioluminescent 
signal (Figure 3B) and there was a significant correlation 
between total flux and the number of cells (R2 = 0.98) 
(Figure 3C). Luciferase-labelled PC3-M-Luc8 cells 
were implanted orthotopically into the prostate gland of 
each of 3 groups of male nude mice. The mice were then 
injected intraperitoneally daily with PBS, dmrFABP5, and 
a combination of dmrFABP5 and SB-FI-26, for 25 days. 
On day 25, there was a large decrease in bioluminescent 
signal in the dmrFABP5 group (2.53×108 units of fleux-
UF) and dmrFABP5 plus SB-FI-26 (3.67×108 UF) group, 
compared with the control (31.5×108 UF). On the basis of 
bioluminescence, our results showed about a 13-fold and 
9-fold suppression in tumor mass by the dmrFABP5 group 
and by the combined inhibitors group over that of the 
control group (Student’s t test, P < 0.0001) (Figure 3D). In 
the control group, 7/7 (100%) mice produced metastases. 
In groups treated with dmrFABP5 alone or combined with 
SB-FI-26, no mice with metastases were detected. These 
results represented significant (100%) suppression of 
metastasis by 100% when compared to the control group 
(Fisher’s Exact test, P < 0.05) (Figure 3E and 3F). When 
tissues were stained histologically after autopsy, all mice 
in the control group developed metastases in the liver 
and lung, but not in bone. No histologically identifiable 
metastases were found in groups treated with dmrFABP5 
or a combination of both inhibitors. Representative stained 
slides are shown in Figure 3G. 
Inhibitor dmrFABP5 suppressed tumorigenicity 
of PC3-M cells in nude mice in a similar way to 
PPARγ antagonist
PC3-M cells were inoculated into the right flank 
of nude mice and the FABP5 inhibitor dmrFABP5 was 
injected subcutaneously to compare its tumor-suppressing 
effect with those of PPARγ antagonists and the chemical 
inhibitor SB-FI-26 (Figure 4). The average size of the 
tumours of the control group were larger than that of 
the test group by the third measurement on day 13 after 
the inoculation, and remained increasingly larger for the 
rest of the experiment (Figure 4A). On termination of 
the experiment or 31 days after inoculation of the cells 
in mice, the average tumor volume in the group treated 
with dmrFABP5 was 161± 61 mm3, compared to 627± 
120 mm3 in the control group; a significant suppression 
of 75% (Student’s t test, p < 0.001) (Figure 4A, and 4B). 
When tumors were weighed on termination at autopsy, 
the differences between control and treated groups were 
similar to those recorded by tumor volume (Figure 4C). 
To study the possible suppression by the PPARγ antagonist 
GW9662 and the possible synergistic effect of dmrFABP5 
with either SB-FI-26 or GW9662, mice were treated 
from day 7 after inoculation in the following 3 ways: 
with dmrFABP5 plus SB-FI-26; with GW9662 or with 
dmrFABP5 plus GW9662 (Figure 4D). Similar to results 
observed in the first round of tumorigenicity studies, 
the average tumour size of the control group was larger 
than that of the test groups by the third measurement on 
day 13 after the inoculation, and remained increasingly 
larger until the end of the experiment (31days after the 
inoculation). Thus the average size of tumors (774 ± 202 
mm3) in the control group was significantly larger than that 
in the 3 treated groups of mice (186 ± 25 mm3 in group 
treated with dmrFABP5 plus SB-FI-26; 252 ± 84 mm3 in 
the group treated with GW9662 alone; and 244 ± 22 mm3 
in the group treated with dmrFABP5plus GW9662). These 
reductions by 76%, 67%, and 68%, were highly significant 
(Student’s t test, p < 0.0001) (Figure 4E). When tumor 
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Figure 3: DmrFABP5 significantly inhibited the tumorigenic and metastatic ability of PC3-M cells implanted 
orthotopically into the prostate gland of nude mice. A. Establishment of stable PC3-M colonies expressing strong bioluminescent 
signals. The three colonies which expressed the highest signals were identified as PC3-M-Luc8, PC3-M-Luc21 and PC3-M-Luc18. B. 
Relationship of the luminescent intensity to the number of cells was assessed by an IVIS imaging system. C. Correlation between the 
bioluminescent flux intensity (photons/second) and the number of cells derived from three different PC3-M-Luc colonies. D. Whole body 
tumour bioluminescent flux produced by each group of nude mice treated with: PBS (control), dmrFABP5 (20mg/kg), or a combination of 
dmrFABP5 (20mg/kg) and SBFI26 (1mg/kg) for 25 days. Although eight mice were used in each group, in one control mouse, the tumour 
mass grew too fast, so it reached 20% of its body size and caused pain to the animal at day 15. Thus this mouse was euthanized and autopsied 
prematurely, and hence was excluded from the resulting assessment. Values were plotted as mean ± SE (n = 7, 8, and 8); the differences 
were assessed by two-tailed unpaired Student’s t test ***, P < 0.0001. E. Numbers of mice which developed one or more metastases in the 
control and the experimental groups after 15 or 25 days of treatment. The differences were assessed by 2-tailed Fisher’s Exact test *, P < 
0.05. F. Ventral bioluminescence images of primary tumours and metastases in all three groups of mice 25 days of treatment. G. Liver and 
lung metastases (arrows) from mice which received injection of PBS (1), dmrFABP5 (2) or combination of SB-FI-26 and dmrFABP5 (3). 
Sections were H&E stained. Magnification ×10 and scale bar is 100 µm.
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Figure 4: DmrFABP5 significantly suppressed tumorigenicity in prostate cancer xenografted mice. A. Average volume of 
tumours produced by PC3-M cells in each group of mice treated with PBS (control) or dmrFABP5 (20mg/kg) for 31 days, starting on day 
7 after inoculation (n = 8). B. Representative mouse and its corresponding tumours from control (1) or dmrFABP5 (2) groups. C. Average 
weight (mg) of tumours from control or treated groups of mice. D. Representative mouse and its corresponding tumours from each of the 
control (1), GW9662 (2), dmrFABP5 and SB-FI-26 (3) or the combination of dmrFABP5 and GW9662 (4) groups. E. Average weight (mg) 
of tumours in the control or experimental groups of mice. F. Average volumes (mm3) of tumours in the control or experimental groups of 
mice. In all tests, the difference between the control and each test group was assessed by 2-tailed unpaired Student’s t test **, p < 0.001; 
***, p < 0.0001.
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weight was measured at autopsy, the differences between 
control and treated groups were similar to those measured 
by tumor volume (Figure 4F). There were no significant 
differences in the average tumor size of mice between 
any 2 of the 3 treated groups and the groups treated with 
dmrFABP5 alone (Student’s t test, p>0.05). 
DmrFABP5 suppressed PPARγ activation
The effect of dmrFABP5 on levels of phosphorylated 
PPARγ (p-PPARγ1 and p-PPARγ2, the presumed 
biologically active forms of PPARγ) was shown in Figure 
5. Western blots using anti-p-PPARγ detected 2 bands 
representing the isoforms of p-PPARγ1 and p-PPARγ2 at 
54 and 57kDa, respectively (Figure 5A). If the levels of 
p-PPARγ1 and p-PPARγ2 in PNT2 were both set at 1 and 
1, relative levels in weakly malignant LNCaP, moderately 
malignant 22RV1, and highly malignant DU145, PC3 and 
PC3-M cells were 9.54 ± 1.81 and 9.5 ± 0.5; 25.4 ± 1.8 
and 47.0 ± 1.7; 26.99 ± 1.72 and 85.5 ± 14.5; 12.08 ± 1.8 
and 30 ± 5; 21.99 ± 2.63 and 80 ± 5, respectively (Figure 
5B). Thus the levels of p-PPARγ, particularly p-PPARγ2, 
were significantly increased in all the malignant cell 
lines studied (Student’s t test, p < 0.001). To investigate 
the effect of dmrFABP5 on p-PPARγ, PC3-M cells were 
treated for 24 hours with the PPARγ antagonist GW9662, 
with the PPARγ agonist Rosiglitazone plus dmrFABP5 
and with the combination of dmrFABP5 and SB-FI-26 
(Figure 5C). If levels of p-PPARγ1 and p-PPARγ2 in 
untreated cells were set at 1 and 1 (Figure 5D), the levels 
in cells treated with GW9662 and dmrFABP5 were 
reduced significantly by 52% and 51%; 50% and 65%, 
respectively (Student’s t test, p < 0.001). Interestingly, 
cells treated with a combination of dmrFABP5 and SB-
FI-26 dramatically reduced the level of p-PPARγ2 by 
90%, and that of p-PPARγ1 by 52%. However, those 
mice treated with rosiglitazone significantly increased 
the levels of both p-PPARγ isoforms (Student’s t test, p < 
0.01) (Figure 5D). When LNCaP cells, which expressed 
very low levels of p-PPARγ1 and 2, were treated with 
wtrFABP5, the levels of both isoforms were increased by 
1- and 0.9- fold, respectively. However, these increases 
were reversed completely by adding dmrFABP5 to the 
cells. Furthermore, addition of dmrFABP5 to LNCaP 
cells reduced the level of p-PPARγ2 by 5-fold (Student’s 
t test, p < 0.001) to a level lower than that obtained in 
the pretreatment group (Figure 5E, 5F). When androgen-
sensitive 22Rv1 cells were treated with wtrFABP5, 
with dmrFABP5 or with a combination of both (Figure 
5G), wtrFABP5 significantly increased the levels 
of both p-PPARγ1 and 2 (Student’s t test, P < 0.01) 
(Figure 5H). However, treatments with dmrFABP5 
significantly suppressed the level of both PPARγ isoforms. 
Furthermore, the promoting effect of wtrFABP5 on levels 
of both p-PPARγ isoforms was completed blocked by 
treatment of mice with dmrFABP5. 
Fatty acid uptake by wtrFABP5 is not interrupted 
by dmrFABP5 in PC3-M cells
To investigate the possible effect of dmrFABP5 on 
fatty acid uptake of PC3-M cells, a fatty acid uptake assay 
was performed using red fluorescence-labelled fatty acid 
BODIPY and a cell analyser/sorter (Figure 6). Unstained 
cells (without BODIPY) were present in M1 zone (Figure 
6A) and BODIPY stained cells were present in M2 zone 
after a 30min incubation (Figure 6B). In contrast to benign 
PNT2, significantly more than 20% and 25% of cells took 
up fatty acid in moderately malignant 22RV1 and highly 
malignant PC3-M (Student’s t test p < 0.01 and p < 0.001) 
cells, respectively. Levels of uptake of fatty acids between 
benign PNT2 and weakly malignant LNCaP cells were 
similar (Figure 6C). The effect of increasing dmrFABP5 
concentrations on fatty acid uptake in PC3-M cells was 
determined using a fixed concentration of BODIPY 
(Figure 6D). When PC3-M cells were incubated with 
dmrFABP5, cellular fatty acid uptake was not significantly 
(Students t-test, p>0.5) changed from 92.9% in the control, 
even when the concentration of dmrFABP5 was increased 
to 0.75 µM. Thus there was no reduction in fatty acid 
uptake in PC3-M cells produced by dmrFABP5 (Figure 
6E).
The level of p-PPARγ in dmrFABP5-treated 
tumours is greatly reduced
The result of immunocytochemical staining is 
shown in Figure 7A. While strong nuclear staining was 
observed in tumour cells of the control group treated with 
PBS (1), very weak staining was seen in tumour cells of 
the experimental group treated with dmrFABP5 (2). The 
antibody specificity was confirmed when the stain was 
completely blocked the p-PPARγ-blocking peptides (3). 
When the staining intensity is expressed by the average 
percentage of the stained cells (Figure 7B); in control 
group, 79.4 ± 3.6% of the tumour cells were stained with 
the anti p-PPARγ antibody. Whereas in the experimental 
group, only 26.2 ± 3.3% of tumour cells were stained. 
Thus dmrFABP5 produced significant (Student t-test, p < 
0.0001) reduction in the staining intensity of p-PPARγ in 
the tumour cells by 67%. 
DISCUSSION
Prostate cancer is the most common male cancer in 
the developed world and therefore it is one of the most 
serious healthcare issues. The main therapeutic strategy 
to treat prostate cancer patients for more than 4 decades 
has been ADT which targets AR and circulating male 
hormones [28]. However, once prostate cancer relapses 
with a more aggressive form to become CRPC, it no 
longer responds to ADT treatment effectively. There have 
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Figure 5: DmrFABP5 reduced the level of phosphorylated PPARγ (p-PPARγ1 and p-PPARγ2) in prostate cancer cells. 
A. Western blot analysis of p-PPARγ1 and p-PPARγ2 in benign and malignant prostate epithelial cells. B. Quantitative assessment of the 
levels of p-PPARγ1 and p-PPARγ2 in benign and malignant prostate cancer cells. C. Effect of 24 h treatments with PPARγ antagonist 
(GW9662), PPARγ agonist (Rosiglitazone), dmrFABP5, or a combination of dmrFABP5 and SB-FI-26 on levels of p-PPARγ1 and 
p-PPARγ2 in PC3-M cells. D. Quantitative assessment: Levels of both p-PPARγ1 and p-PPARγ2 in untreated PC3-M cells were set at 1; 
levels in the other treated cells were obtained by comparison with those in untreated PC3-M. E. Effect of 24 h treatments with wtrFABP5 
or with a combination of wtrFABP5 and dmrFABP5 on levels of p-PPARγ1 and p-PPARγ2 in LNCaP cells. F. Quantitative assessment: 
Levels of p-PPARγ1 and p-PPARγ2 in control 22RV1 cells were set at 1; levels in the other treated cells were obtained by comparison with 
those in control. G. Effect of 24 h treatments with wtrFABP5, or with dmrFABP5 on levels of p-PPARγ1 and p-PPARγ2 in 22RV1 cells. H. 
Quantitative assessment: Levels of both p-PPARγ1 and p-PPARγ2 in the control were set at 1; levels in the other treated cells were obtained 
by comparison with those in controls. For each Western blot, anti-β-actin was also used to normalize for possible loading errors. Results 
(mean ± SE) were obtained from three separate experiments and the differences were assessed by 2-tailed unpaired Student’s t test. *, p < 
0.05; **, p < 0.001. 
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Figure 6: Fatty acid uptake by different prostate epithelial cell lines and the suppressive effect of dmrFABP5 in 
PC3-M cells. A. Representative histograms for unstained PNT2, LNCaP, 22RVI and PC3-M cells without adding BODIPY-labelled fatty 
acid. The marker M1 highlights negative peaks of the subclass control. B. Representative histograms for fluorescence of stained PNT2, 
LNCaP, 22RVI and PC3-M cells 30 min after adding BODIPY-fluorescently labelled fatty acid; the marker M2 is placed to the right of 
M1 to highlight positive events (total percentage of cells with BODIPY-labelled fatty acid). C. Percentages of cells taking up BODIPY-
labelled fatty acid from different prostate epithelial cell lines. D. Representative histograms for fatty acid uptake of PC3-M cells at a fixed 
concentration of BODIPY-labelled fatty acid in the presence of different concentrations of dmrFABP5. M1, unstained cells; M2, stained 
cells. E. Percentages of cells with fluorescently-labelled fatty acid in PC3-M control (untreated) and those wells treated with different 
concentrations of dmrFABP5 for 30 min with a fixed concentration of BODIPY-labelled fatty acid. Fluorescent intensity of each cell line 
was measured with an EPICS XL Cytometer (Beckman) at 570nm and data analysis was performed with SYSTEM II™ Software. Values 
were plotted as mean ± SE (error bars). The differences between the control and the experimental groups were assessed by 2-tailed unpaired 
Student’s t test. *, p < 0.01; **, p < 0.001.
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been different hypotheses on how the androgen-dependent 
cells transform into androgen-independent cells. The main 
theory to date is that the biological sensitivity of AR is 
selectively amplified after the first round of ADT to such 
an extent that even micro-quantities of the remaining 
male hormone in peripheral blood can still promote the 
malignant progression of CRPC cells [29]. Thus treatment 
of patients with CRPC by further ADT is generally used 
in present clinical practice. However, contrary opinions to 
this practice have been expressed recently and it has been 
suggested that continued use of ADT in CRPC may lead to 
a therapeutic dead end [30, 31]. Our own study suggested 
that AR changes caused by ADT are not always relevant 
to malignant progression of CRPC cells. Thus targeting 
instead the FABP5- PPARγ-VEGF axis, which we suggest, 
gradually replaces the AR-mediated signalling pathway 
in tumour progression, could be an alternative way for 
treatment of CRPC [7]. In fact, a number of recent studies 
have confirmed the promoting role of PPARγ in malignant 
progression of prostate cancer and that the stimulation 
produced by FABP5- transported fatty acids plays an 
important role in PPARγ activation [32-34]. In this work, 
we have used the novel bio-inhibitor dmrFABP5 in nude 
mice to treat CRPC successfully by suppressing the 
biological activity of FABP5. 
The mutant protein dmrFABP5 has a very similar 
structure to that of wtrFABP5, but the mutant is almost 
incapable of binding to fatty acids, as shown in Figure 
1C and 1D. Here for the first time, we have shown 
that dmrFABP5 has a dominant negative effect on 
suppressing the biological activity of FABP5 and hence 
the tumorigenicity and metastatic ability of PC3-M cells. 
Thus, dmrFABP5 produced a significant suppression of 
PC3-M proliferation, invasiveness, migration and colony 
formation in vitro. When it was tested in nude mice, 
dmrFABP5 was highly effective in suppressing both the 
primary tumour in the prostate gland and the subcutaneous 
tumour in the flank. Thus dmrFABP5 produced on average 
a 13-fold reduction in tumour mass in the prostate gland 
and 3-fold reduction in mass of the subcutaneous tumours 
(Figures 3 and 4). Most importantly, dmrFABP5 produced 
a 100% suppression of metastasis in mice with CRPC 
cells implanted into the prostate gland (Figure 3). In our 
previous study, when the biological function of FABP5 
was inhibited by SB-FI-26 in PC3-M cells, a significant 
decrease in cell proliferation, invasion, migration and 
anchorage-independent growth in vitro was observed 
[35-37]. SB-FI-26 showed efficient anti-tumour effects in 
Figure 7: Immunocytochemical detection of p-PPARγ in tumours produced by PC3-M in nude mice. PC3-M cells were 
orthotopically inoculated into prostate glands of the nude mice. The mice in the control group and those in the experimental group were 
injected peritoneally with PBS and dmrFABP5, respectively. A. Representative immunocytochemical staining of sections of the tumour 
tissues: 1) A tissue section from tumours of the control group treated with PBS. 2) A tissue section from tumours of the experimental group 
treated with dmrFABP5. 3) A tissue section from a tumour of the control group: the stain was blocked with a p-PPARγ blocking peptide 
as a negative control. B. Quantitative assessments of the average percentage numbers of the stained cells in control and in experimental 
groups. The difference between the control and the experimental group was assessed by 2-tailed paired Student’s t test. ***, p < 0.0001.
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both the mouse cell model for primary tumours implanted 
in the prostate gland (by 4.9- fold) and when inoculated 
in the flank (by 52%). Moreover, SB-FI-26 treatment of 
tumour-bearing nude mice suppressed metastases in 50% 
of these rodents. When dmrFABP5 was compared to SB-
FI-26, the suppressive effect of dmrFABP5 was 2.7-fold 
higher in tumours growing in the prostate gland, and 30% 
higher in tumours growing in the flank. Furthermore, the 
suppressive effect of dmrFABP5 on metastasis in the 
mice was twice that of SB-FI-26. These results suggest 
that the suppressive effect of dmrFABP5 on tumour 
progression is much stronger than that of SB-FI-26. Thus 
this experimental therapeutic result for dmrFABP5 in our 
current study is a great improvement over that obtained 
by the chemically-synthesized inhibitor SB-FI-26 in our 
previous work [24].
In our previous report, the increased level of 
FABP5 plays an important role in promoting malignant 
progression in CRPC model cell systems by binding 
and transporting increased amounts of fatty acids which, 
in turn, stimulate the nuclear receptor PPARγ [16]. In 
this work we have shown that the treatment of PC3-M 
cells with the PPARγ antagonist, GW9662, produces a 
suppression of tumour growth similar to that obtained 
with dmrFABP5 (Figure 4). This result suggests that the 
suppressive mechanism of dmrFABP5 is related to the 
FABP5- PPARγ-signal transduction pathway [7]. Fatty 
acid-uptake results reported here show that the uptake 
of fatty acids is increased with increasing malignancy 
of the prostate cancer cells tested (Figure 6), indicating 
that enhanced amounts of fatty acids are taken up by the 
cancer cells and that at least part of them may be used to 
stimulate and thus activate PPARγ. In our previous work, 
SB-FI-26 produced a remarkable reduction in fatty acid 
uptake into PC3M cells. Thus it was suggested that SB-
FI-26 may be a competitive inhibitor of fatty acids for 
FABP5 and hence prevent intra- and extra-cellular fatty 
acids from being transported into the cytoplasm [24]. The 
reduced uptake of fatty acids produced by SB-FI-26 may 
result in a reduction or cessation of the stimulation of 
PPARγ by fatty acids. Thus PPARγ may no longer be able 
to upregulate the down-stream cancer-promoting genes, 
such as VEGF, and to suppress those genes connected to 
apoptosis [7]. However, in our present work, dmrFABP5 
does not produce any noticeable changes in uptake of fatty 
acids into PC3-M cells (Figure 6); a result which suggests 
that dmrFABP5 acts through a mechanism different from 
that of SB-FI-26. 
Our recent study showed that it is the FABP5-
PPARγ-VEGF signalling transduction axis, not the 
androgen receptor-initiated pathway, which is a dominant 
route for transduction of malignant signals in CRPC 
cells [7]. In this axis, the role of PPARγ is essential. 
Although we have found that the total PPARγ expressed 
in the malignant prostate cell lines is not higher than 
that in the benign PNT2 cells, both phosphorylated 
(presumed biologically-activated) PPARγ isoforms 
p-PPARγ1 and p-PPARγ2 [24] increase generally with 
increasing cellular malignancy. Both phosphorylated 
PPARγ isoforms are increased by wtrFABP5 and these 
increases can be inhibited by dmrFABP5 (Figure 5) in 
LNCaP cells which express low levels of phosphorylated 
PPARγ. Furthermore, the levels of the PPARγ isoforms in 
PC3-M cells are increased further by the PPARγ agonist, 
rosiglitazone or are greatly reduced by treatment with 
dmrFABP5, with GW9662, or with dmrFABP5 plus SB-
FI-26 (Figure 5). These results suggest that dmrFABP5 
may act to inhibit the stimulation of fatty acid transport 
induced by wild type FABP5 and thereby it can prevent 
activation or phosphorylation of PPARγ. This is supported 
by the immunocytochemical staining results (Figure 7) 
that dmrFABP5 caused significant reduction of p-PPARγ 
staining intensity in tumour tissues by 67%. PPARγ is a 
receptor for fatty acids localised in the nuclear membrane 
and this receptor plays an important role in promoting 
metastasis in prostate cancer [32]. Although both 
dmrFABP5 and SB-FI-26 suppress CRPC by affecting 
PPARγ, the inhibition of PPARγ phosphorylation by 
dmrFABP5 is unlikely to be caused by inhibition of 
fatty acid uptake in contrast to the inhibition observed in 
PC3-M cells treated with SB-FI-26. 
It has been suggested that SB-FI-26 is a weak 
agonist of PPARγ in prostate cancer cells [21]. Since SB-
FI-26 suppresses fatty acid uptake by displacing fatty acids 
which bind to FABP5, it is possible that some SB-FI-26 
is delivered to activate PPARγ, but in a weaker way than 
with the fatty acids. This conclusion may be the reason 
why SB-FI-26 is a less effective inhibitor than dmrFABP5 
in PC3-M cells. Since the inhibitory effects of dmrFABP5 
and SB-FI-26 are exerted at 2 different points in the same 
signal transduction pathway, no further suppression is 
anticipated when they are used in combination. Since the 
exact route of fatty-acid transportation and delivery to 
PPARγ is not known, the reason why dmrFABP5 inhibits 
PPARγ is not fully understood. It has been suggested that 
actual physical interactions between FABPs and PPARs 
are necessary for an effective delivery of fatty acids 
[38]. Since the structure of dmrFABP5 is very similar 
to that of the wtFABP5, it is possible that dmrFABP5 
occupies the same binding site as wtFABP5 in PPARγ and 
thereby prevents wtFABP5 from delivering fatty acids to 
PPARγ. Further study is needed to understand more fully 
the mechanisms involved in the suppressive effect of 
dmrFABP5 on PPARγ activation. 
Previous work has suggested that the dependency 
of the prostate cancer cells on the FABP5-related pathway 
is increased gradually with a concomitant reduction 
in dependency on the AR-initiated pathway, until the 
former becomes completely dominant [7]. In this study, in 
androgen-responsive, moderately-malignant 22RV1 cells, 
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dmrFABP5 produces a reduction in both phosphorylated 
isoforms of PPARγ by an average of 33.5% (Figure 5). 
This level of reduction is smaller than that of about 50% 
produced in the androgen-independent, highly malignant 
PC3-M cells. These results suggest that the proportion 
of phosphorylated PPARγ capable of regulation by the 
FABP5-related pathway is higher in PC3-M cells than 
that in 22RV1 cells. This result suggests that treatment by 
suppression of the FABP5-pathway is likely to be more 
effective in AR-negative CRPC cells. In conclusion, 
the novel FABP5 inhibitor dmrFABP5 suppresses the 
malignant progression of CRPC by blocking fatty acid-
stimulation of PPARγ and thereby it curtails its up- or 
down-regulating effect on the down-stream cancer-
promoting or -suppressing genes in the nude mouse model 
of CRPC.
MATERIALS AND METHODS
Construction of expression vectors
Construction of expression vectors was carried out 
as described previously [16]. After single and double 
mutations were generated by site-directed mutagenesis 
in the fatty acid-binding motif of human FABP5 cDNAs, 
the wild type, the single- and the double-codon mutated 
FABP5 cDNAs were first cloned into the pBluescript II 
SK (Qiagen) vector and then excised from the vector with 
restriction enzymes KpnI and PstI. The 3 cDNAs were 
then separately inserted into the bacterial expression 
vector pQE32 (Qiagen) which had been linearized with 
KpnI and PstI. The constructs were transformed into 
competent E. coli cells to form 3 separate bacterial pools 
which harboured cDNAs for wild type FABP5, single-
point-mutated FABP5 and doubly- mutated FABP5. 
The correct orientations of the inserted cDNAs in the 
constructs were confirmed by nucleic acid sequence 
analysis. The recombinant proteins produced by these 
3 pools of transformed E.coli cells were named as wild 
type recombinant FABP5 (wtrFABP5), singly-mutated 
recombinant FABP5 (smrFABP5) and doubly-mutated 
recombinant FABP5 (dmrFABP5), respectively. The final 
product smrFABP5 was obtained by changing Arg109 to 
Ala109 (R to A); and dmrFABP5 was obtained by changing 
Arg109 to Ala109 (R to A) combined with the changing of 
Arg129 to Ala129 (R to A) in the parental wtrFABP5. 
Expression and purification of recombinant 
FABP5s
The wild type and 2 mutant FABP5 cDNAs were 
cloned into pQE32 expression vectors. The 3 recombinant 
FABP5s were produced in the BL21 strain of E. coli cells. 
After the initial incubation, the E coli cells were induced 
by 1mM IPTG. Bacterial samples were removed every 
hour for up to 6 hours after IPTG induction. Bacterial 
cells were harvested and lysed in lysis buffer, as described 
previously [16]. Recombinant FABP5s were separated 
from bacterial proteins by affinity chromatography on 
a Ni-NTA agarose column (Qiagen). Isolated proteins 
were dialyzed against PBS at 4˚C for 4 hours to remove 
imidazole and stored at -80˚C. The authenticity of the 
recombinant FABP5s was checked by Western blot 
analyses using both the Penta-His antibody (Qiagen) 
and the polyclonal rabbit anti-human FABP5 antibody 
(Hycult). Before the ligand binding assay, possible binding 
of fatty acids to wtrFABP5 was removed by delipidation 
using Lipidex-1000 (Sigma) [39].
Ligand binding assay
The fatty acid-binding ability of all purified 
recombinant FABP5s was examined by the DAUDA 
displacement assay, which used fatty acids to displace 
the fluorescently-labelled fatty acid analogue DAUDA 
(Cayman). The excitation wavelength used for DAUDA 
was fixed at 345 nm, and the emission wavelengths for 
other molecules were collected over the range of 450-
600 nm. Fluorescence-peak-emission wavelength for 
wtrFABP5 was determined by setting up the experiments 
as PBS, 3µM wtrFABP5, 2µM DAUDA and 3µM 
wtrFABP5 in 2µM DAUDA. Fatty acid-binding ability of 
the 3 FABP5s to 2µM DAUDA was tested by monitoring 
the change in fluorescent intensity and wavelength at peak 
emission [40] for each recombinant FABP5 in the present 
or absence of 2µM palmitic acid. 
Cell lines and chemical inhibitor SB-FI-26
The benign prostate cell line PNT2 [41], the highly-
malignant, androgen-independent cell lines DU145[42], 
PC3 [43], and PC3-M [44], the moderately-malignant, 
androgen-responsive cell line 22RV1 [45], and the 
weakly malignant cell line LNCaP [46] were cultured and 
maintained in 1640 medium (Invitrogen) supplemented 
with 10% (v/v) FCS (Biosera), 100 U/mL penicillin and 
100μg/mL streptomycin (Invitrogen). For LNCaP cells, 
100μg/mL sodium pyruvate (Sigma) was added to the 
culture medium. The chemical inhibitor SB-FI-26 was 
purchased from ChemDiv, dissolved in DMSO, and stored 
at -20˚C. Before experimental work, a short tandem repeat 
(STR) profile was obtained on the genomic DNA from 
each cell line used. The authenticity of each cell line 
was confirmed when more than 80% of the STR profile 
matched that of DSMZ. 
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Cell viability and proliferation assay
PC3-M cells (5×104) were plated in triplicate in 
96-well plates and incubated overnight at 37oC. Cells 
were treated with different concentrations of dmrFABP5 
(5-70µM) and SB-FI-26 (25-125µM) for 24 h. Cell 
viability was assessed using the MTT assay, as described 
previously [16].
Cell migration assay
The scratched wound healing migration assay was 
carried out to evaluate the effect of the inhibitor on the 
migration rate of PC3-M cells. Wounds were generated 
by scratching the cell monolayer with a blue pipette tip. 
The inhibitor dmrFABP5 was then added to the culture 
medium. The wound area was photographed under the 
microscope and resultant images assessed using ImageJ 
software.
Invasion assay
This assay was performed as originally described 
[47] but with some modifications. PC3-M cells in serum-
free medium were seeded in triplicate in the upper 
Boyden chamber (BD Biosciences) at a density of 2.5× 
104 cells per well. Complete medium was added to the 
lower chambers. After 3 hours of incubation at 370C, the 
inhibitors were added to the upper chambers. After 24 h of 
incubation, cells which invaded the lower chambers were 
stained with crystal violet and counted.
Soft-agar assay
Low melting agarose was transferred to 6-well 
plates and after setting, 5×104 cells/well were seeded 
on top of the set in 200µl of medium alone or media 
containing different FABP5 inhibitors. After 2 weeks 
incubation at 370C, colonies larger than 300µm were 
counted in a similar way to that described previously [16].
Nude mouse assay to test tumorigenicity and 
metastasis
PC3-M cells were transfected with the pGL4.50 
[luc2/CMV/Hygro] vector (Promega) using FuGene 
HD transfection reagent (Promega) following the 
manufacturer’s instructions. Individual colonies were 
isolated by ring cloning and 3 colonies that stably 
expressed the highest bioluminescent signals were 
identified using D-luciferin (Promega) with a Varioskan 
Flash Reader (Thermo Scientific). The relationship of the 
luminescent intensity with the number of cultured cells 
was assessed by an IVIS imaging system (Perkin Elmer). 
Cells (5×105) from PC3-M- luc2 colony were suspended 
in 30µL PBS and orthotopically implanted into 24, 
8-10 weeks old male Balb/c nude mice (Charles River, 
UK) by direct injection into the dorsal prostate. Mice 
are too small in which to distinguish zonal structuresof 
the prostate [48]. One-week later, tumour-bearing mice 
were divided into 3 groups (8 each) and subjected to the 
following intraperitoneal injections: 1) control with PBS; 
2) dmrFABP5 (20mg/kg); 3) dmrFABP5 (20mg/kg) plus 
SBFI26 (1mg/kg). Injections were repeated every two days 
for 25 days and the metastatic foci were monitored weekly 
using IVIS after mice were injected subcutaneously with 
D-luciferin (150 mg/kg). Bioluminescent images were 
analysed using the Living Imagine software (Xenogen) 
and recorded as total photons/second (p/s) within each 
defined region. 
Nude mouse tumorigenicity assay
PC3-M cells (2×106) in 200µL PBS were injected 
subcutaneously into the right flank region of the mouse 
(6-8 week old) to compare the suppressive effects 
produced by dmrFABP5 and the PPARγ antagonist or 
agonist. In the first round, 2 groups of mice (8 each) were 
used: 1) control with PBS; 2) dmrFABP5 (20mg/kg); both 
groups were injected from day 7 after inoculation. In the 
second round, 4 groups of mice (5 each) were used and 
at day 7 after inoculation, each group was subjected to 
different intra-tumoural injections: 1) control with PBS; 
2) PPARγ antagonist (GW9662, 1mg/kg); 3) dmrFABP5 
plus SBFI26 (Sigma, UK); 4) dmrFABP5 plus GW9662. 
The injections were repeated every 2 days for 30 days, 
tumour size was measured every 3-4 days and the volume 
calculated using the formula of L×W×H×0.5236 [49]. All 
animal work was conducted in accordance with Cancer 
Research UK Guidelines under Home Office Project 
Licence PPL 40/3578 (to YK). 
Fatty acid uptake assay
Assay for uptake of fatty acids was performed using 
red fluorescently-labelled BODIPY [50]. The fluorescence 
intensity from cells before and 30 minutes after adding 
BODIPY was measured to determine fatty acid uptake. 
In inhibition and competition experiments, different 
concentrations of dmrFABP5 with the same concentration 
of labelled BODIPY were added directly to the highly-
malignant PC3-M cells.
Immunocytochemical staining for p-PPARγ
Histological section (cut at 4µm) slides were 
dewaxed and incubated with 1% BSA/PBS for ½ hr 
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at room temperature to block background staining. 
The rabbit polyclonal anti p-PPARγ (#PA5-36763, 
Thermofisher) was applied at a dilution of 1:1500 in 
1%BSA/PBS for 1hr at room temperature in a moisture 
chamber. Immunocytochemical staining was carried 
out using an enhanced HRP labelled polymer system, 
EnVision+System,peroxidase (DAB) (Dako Ltd, Ely, 
UK). The sections were then washed in running tap water 
before being counterstained in Mayers’ haemalum. They 
were then dehydrated through graded ethanol and xylene 
and were mounted in DPX (Merck, Poole, UK). For the 
blocked control, mix PPARγ blocking peptide (Santa Cruz 
#sc7273P) with p-PPARγ antibody at a final concentration 
of 0.2mg/ml with respect to peptide and 1:5000 with 
respect to antibody. Incubate at 37°C for 3hr followed by 
ON at 4°C. The staining intensity was calculated by the 
percentages of the stained cells. For each slide, four fields 
of 100-200 cells were counted.
Statistical analysis
Student’s t-test and Fisher’s Exact test were carried 
out using GraphPad Prism software to compare the 
differences of the means between control and experimental 
groups. The difference is regarded as significant when p < 
0.05; in the results, p value is represented by asterisks as 
follows: *, p < 0.05; **, p < 0.001; ***, p < 0.0001.
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